Financial HealthSTXS likely ended 2024 with approximately $12M in cash and no debt, which could allow for the commercialization of its next-generation product ecosystem and reach profitability without additional financing.
Product LaunchMAGiC catheter launch in Europe is a critical growth driver due to its immediate impact on per-procedure economics and compatibility with GenesisX.
Regulatory ApprovalApproval of the Magbot catheter in China is another key win, ahead of what should be a big year for STXS in 2025.